Neurol. praxi. 2024;25(4):315-320 | DOI: 10.36290/neu.2024.049

Fenfluramine

MUDr. Ondřej Horák
Centrum pro epilepsie Brno, Klinika dětské neurologie LF MU a FN Brno

In the following review article, we introduce fenfluramine - an "old-new" drug, used in the past for the treatment of obesity and now relatively newly registered in the European Union, the USA and the UK as an orphan drug for the therapy of epileptic seizures associated with Dravet and Lennox-Gastaut syndrome, i.e. with severe and generally ultrarefractory epileptic encephalopathies. The mechanism of action of fenfluramine is based on interaction with serotoninergic and sigma-1 receptors, which, in addition to reducing seizure activity, promises to patients cognitive, emotional, and behavioral benefits. Efficacy and a safety profile have been proved in four randomized phase III trials and subsequently confirmed in two follow-up open-label studies.

Keywords: Dravet syndrome, Lennox­‑Gastaut syndrome, antiseizure medication, efficacy.

Received: July 22, 2024; Revised: July 22, 2024; Accepted: August 5, 2024; Prepublished online: August 5, 2024; Published: September 10, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák O. Fenfluramine. Neurol. praxi. 2024;25(4):315-320. doi: 10.36290/neu.2024.049.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bishop KI, Isquith PK, Gioia GA, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 longterm extension study in children/young adults with Dravet syndrome. Epilepsy Behav. 2021;121:108024. Go to original source... Go to PubMed...
    2. Hatini PG and Commons KG. A 5-HT1D­‑receptor agonist protects Dravet syndrome mice from seizure and early death. Eur. J. Neurosci. 2020;52:4370-4374. doi:10.1111/ejn.14776 Go to original source... Go to PubMed...
    3. Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox­‑Gastaut Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2022;79(6):55-564. doi:10.1001/jamaneurol.2022.0829 Go to original source... Go to PubMed...
    4. Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox­‑Gastaut syndrome: Interim analysis of an open­‑label extension study. Epilepsia. 2023;64(1):139-151. doi: 10.1111/epi.17431. Epub 2022 Nov 9. PMID: 36196777; PMCID: PMC10099582. Go to original source... Go to PubMed...
    5. Lagae L, Sullivan J, Knupp KG, et al (FAiRE DS Study Group). Fenfluramine hydrochloride for thetreatment of seizures in Dravet syndrome: a randomised, double­‑blind, placebo controlled trial. Lancet. 2019;394(10216):2243-54. Go to original source... Go to PubMed...
    6. Martin P, Czerwiński M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacol Res Perspect. 2022;10:e00959. Go to original source... Go to PubMed...
    7. Martin P, de Witte PAM, Maurice T, et al. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy & Behav. 2020;105:106989. doi:10.1016/j.yebeh.2020.106989 Go to original source... Go to PubMed...
    8. Martin P, Reeder T, Sourbron J, et al. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22:8416. Go to original source... Go to PubMed...
    9. Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment­‑resistant seizures in patients with Dravet syndrome receiving stiripentol­‑inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300-8. Go to original source... Go to PubMed...
    10. Reeder T, Martin P, Sourbron J, et al. Dual Activity of Fenfluramine (Fintepla®) as a Serotonin Receptor Agonist and Positive Sigma-1 Receptor Modulator: Implication for Disease Modification in Developmental and Epileptic Encephalopathies. Poster presented at the American Epilepsy Society Annual Meeting, Chicago, IL, 2021;December 3-7.
    11. Schoonjans A­‑N, Lagae L, Ceulemans B. Low­‑dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015; 8: 328-38. Go to original source... Go to PubMed...
    12. Sourbron J, Lagae L. Serotonin receptors in epilepsy: Novel treatment targets? Epilepsia Open 7. 2022; 31-246. doi:10.1002/epi4.12580 Go to original source... Go to PubMed...
    13. Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti­‑epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191. Go to original source... Go to PubMed...
    14. Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla®) provides longterm clinically meaningful reduction in seizure frequency: Analysis of an ongoing open­‑label extension study. Epilepsia. 2020;61(11):2396-404. Go to original source... Go to PubMed...
    15. Tupal S, Faingold CL. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure induced sudden death in a mouse model of SUDEP. Epilepsy Res. 2021;177:106777. Go to original source... Go to PubMed...
    16. Wirrell EC, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022;63(7):1761-1777. doi: 10.1111/epi.17274. Epub 2022 May 12. PMID: 35490361; PMCID: PMC9543220. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.